IP Verse

Actavis competitive analysis

Explore the latest publications and patents granted to Actavis, showcasing their recent innovations and technological advancements.

Explore patent oppositions filed by Actavis against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 25, 2025

Patent Number	Title	Applicant	Opposition Date
Get instant updates on new opposition filings by the company
EP2269603	Treatment Of Solid Tumours With Rapamycin Derivatives	NOVARTIS	Feb 22, 2016
EP2377536	Methods Of Using Sustained Release Aminopyridine Compositions	ACORDA THERAPEUTICS	Dec 5, 2013

Discover the latest PTAB cases involving Actavis, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 30, 2025

Proceeding Number	Filing Date	Petitioner	Respondent	Status
Get alerts for PTAB Cases involving Actavis
IPR2017-01946	Aug 15, 2017	ACTAVIS ELIZABETH	NOVARTIS PHARMACEUTICALS	Final Written Decision
IPR2017-01104	Apr 4, 2017	ACTAVIS	ABRAXIS BIOSCIENCE	Terminated-Settled
IPR2017-01103	Apr 4, 2017	ACTAVIS	ABRAXIS BIOSCIENCE	Terminated-Settled
IPR2017-01101	Apr 4, 2017	ACTAVIS	ABRAXIS BIOSCIENCE	Terminated-Settled
IPR2017-01100	Apr 4, 2017	ACTAVIS	ABRAXIS BIOSCIENCE	Institution Denied
IPR2017-00853	Feb 8, 2017	ACTAVIS LABORATORIES FL	JANSSEN ONCOLOGY	Final Written Decision
IPR2014-01126	Jul 10, 2014	ACTAVIS	RESEARCH	Institution Denied

IP litigation analysis comparing Actavis with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 25, 2025

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced	Strategy Type
ACTAVIS PTC EHF	1	-	-	-	Highly Aggressive
NOVARTIS	6	406	-	21	Defensive